Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

Understanding Latent Tuberculosis: A Moving Target

(2010) P. L. Lin et al.   JOURNAL OF IMMUNOLOGY

Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection

(2009) Tianyu Zhang et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view

(2009) Carleitta Paige et al.   CELLULAR MICROBIOLOGY

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis

(2009) Mary G. Boy et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Phase 1 Dose-Escalation Study of CP-690 550 in Stable Renal Allograft Recipients: Preliminary Findings of Safety, Tolerability, Effects on Lymphocyte Subsets and Pharmacokinetics

(2008) E. van Gurp et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia

(2008) Elizabeth Kudlacz et al.   EUROPEAN JOURNAL OF PHARMACOLOGY